ARCT — Arcturus Therapeutics Holdings Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1768224 ·
Last close
$14.34
Market Cap
$407.59M
52W High
$14.53
52W Low
$5.50
ADV30
901,369
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 880,000 | — | -25,545,000 | -23,785,000 | 224,310,000 | 191,483,000 | 52,502,000 |
| Mar 2026 | 610,000 | — | -28,931,000 | -26,964,000 | 245,411,000 | 211,375,000 | 54,049,000 |
| Dec 2025 | 3,081,000 | — | -31,307,000 | -29,079,000 | 271,148,000 | 230,909,000 | 57,163,000 |
| Sep 2025 | 14,153,000 | — | -16,512,000 | -13,448,000 | 282,343,000 | 180,360,000 | 57,784,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-72,729,000
Investing CF
$-41,000
Financing CF
$12,929,000
CapEx
$-318,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.31
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-565,339,000
Inventory
—
Receivables
$1,813,000
ST Investments
—
EBIT TTM
$-91,809,000
Pretax Income TTM
$-93,280,000
Interest Exp TTM
$0
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$29,368,000
EBITDA
$-99,548,000
Free Cash Flow
$19,258,624
Enterprise Value
$213,740,272
Total Cash
$191,483,008
Total Debt
$22,933,000
Shares Out
28,423,069
Trailing EPS
$-3.33
Book Value
$6.04
ROE
-46.3%
ROA
-24.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 67,221,000 | -76,260,000 | -65,783,000 | 271,148,000 | 57,163,000 | — | -74,271,000 |
| Dec 2024 | 138,389,000 | -95,669,000 | -80,941,000 | 344,069,000 | 103,091,000 | — | -59,747,000 |
| Dec 2023 | 157,748,000 | -78,205,000 | -29,725,000 | 429,402,000 | 150,889,000 | — | -18,099,000 |
| Dec 2022 | 205,755,000 | 12,177,000 | 9,349,000 | 450,387,000 | 180,075,000 | — | 31,993,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.72
Max Pain — expiry 2026-09-18
max pain strike: $7.50 · spot: $14.34 · call oi: 3,176 · put oi: 449
Expected Move to 2026-09-18:
±$3.43
(23.88%) —
implied range
$10.92 –
$17.77
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | $407.98M | $6.87 | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $410.67M | $14.10 | — |
| PRLD | Prelude Therapeutics Inc | $420.01M | $6.47 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $395.35M | $6.80 | — |
| LRMR | Larimar Therapeutics, Inc. | $420.73M | $4.05 | — |
News headlines (Yahoo Finance, 1h cache)
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
2026-08-12 01:04 · Yahoo
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
2026-07-20 20:01 · Yahoo
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
2026-06-05 09:02 · Yahoo
Arcturus Therapeutics Q1 Earnings Call Highlights
2026-05-07 21:39 · Yahoo
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players
2026-08-21 18:54 · Yahoo
Moderna And Merck's Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
2026-08-20 20:07 · Yahoo
Arcturus Therapeutics Q2 Earnings Call Highlights
2026-08-06 22:04 · Yahoo
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
2026-07-28 20:01 · Yahoo
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
2026-07-03 11:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.